On World AIDS Day…

On World AIDS Day…

Dec 01, 2016

  • 7 million people are living with HIV, 40% don’t know their status
  • New HIV infections among children have declined by 50% since 2010.
  • The incidence of HIV/AIDS is increasing among young gay men.
  • UNAIDS released a report showing 18.2 million people are now on antiretroviral therapy. However, it found women aged between 15 and 24 were at great risk.
  • The number of people living with HIV on antiretroviral therapy has increased by about a third, 3 million more than the 15 million by 2014.
  • In high income countries, 31% of people living with HIV are now over the age of 50 due to antiretroviral therapy.
  • Recent updated UNAIDS estimates indicate that US$ 26.2 billion will be required for the AIDS response in 2020, with US$ 23.9 billion required in 2030.
  • Brazil represents the largest number of people living with HIV in Latin America at 47%. Worldwide, it is one of 15 countries which represent 75% of the global number of people living with HIV.
  • Western and central Africa are current areas of concern – they account for 18% of people living with HIV. Lack of treatment access means the area also accounts for 30% of all Aids-related deaths globally
  • In June 2016, GSK made a groundbreaking deal to make the HIV drug Tivicay available for Botswana’s national effort to test and treat as many citizens as possible.
  • Cipla offers free antiretroviral technology to any African nation looking to produce their own drugs. In 2001, India’s Cipla had introduced the world’s first 3-in-1 fixed dose combination (Stavudine, Lamivudine, and Nevirapine). Now, a third of people living with HIV in 115 countries are taking this drug.
  • Gilead Sciences Inc. has begun marketing its HIV treatment Truvada to prevent infection with the virus that causes AIDS.

Downloads

Article in PDF

Recent Articles
  1. Business Cocktail
  2. Bristol-Myers Squibb’s Opdivo & Yervoy Combo Trial; Sarepta’s Gene Therapy SRP-9001 for DMD;...
  3. Merck, Gilead teams up for HIV treatment; Bright Future for Sanofi/Regeneron’s Libtayo; Roche acq...
  4. WORLD AIDS DAY – 2018
  5. Pfizer’s RSV Vaccine; Forte Biosciences’ Atopic Dermatitis Asset; Bone Therapeutics’ Osteoarthrit...
pharma-news-for-gilead-merck-astellas
Notizia - Recent Pharma, Healthcare and Biotech Happenings

Gilead and Merck Announce Encouraging Phase II Results of Islatravir and Lenacapavir Combo; REGENXBIO Highlights Positive Data from Phase II ABBV-RGX-314 Wet AMD Study at AAO 2024; FDA Greenlights Astellas’ VYLOY for Advanced Gastric and GEJ Cancer Therapy; Merck’s CAPVAXIVE Vaccine Yields Strong Immune Response in Adults Vulnerable to Pneumococcal Disease; FDA Postpones LUMAKRAS Colorectal Cancer Verdict to Early 2025

Pharma News for Gilead, Roche, AstraZeneca, Genentech, Mirati, Pfizer
Notizia - Recent Pharma, Healthcare and Biotech Happenings

Gilead Sciences’ Sunlenca Approval; FDA Approves Roche’s CD20xCD3 Bispecific Antibody Lunsumio; EU Approves AstraZeneca’s Imfinzi Plus Chemo; Pfizer Files Blockbuster Hope Etrasimod for Ulcerative Colitis; FDA Approves Mosunetuzumab for R/F Follicular Lymphoma; FDA Breakthrough Therapy Designation to Adagrasib Plus Cetuximab for KRAS G12C–Mutated Advanced CRC

clinical-diagnostics-market-outlook
Articles

Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market

AIDS
HIV
HIV infection
WORLD AIDS DAY
loader